Beyond Air raises up to $30.1M in private placement for LungFit PH launch

Beyond Air, Inc.

Gross proceeds of $10.2M upfront from 167,011 shares and pre-funded warrants; up to $30.1M if all warrants exercised.
Series A warrants (1.8M shares) expire 1 year or 45 days after FDA approval of LungFit PH II; Series B warrants (1.8M shares) expire 5 years.
CEO Robert Goodman and CFO Dan Moorhead participate at $5.76/share; institutional investors at $5.66/share.
Net proceeds for working capital and general corporate purposes; closing expected July 31, 2026.
Cantor Fitzgerald leads placement agents; registration statement to be filed within 15 days of closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.